Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

Joanna Kapeleris; Juliana Müller Bark; Shanon Ranjit; Darryl Irwin; Gunter Hartel; Majid Ebrahimi Warkiani; Paul Leo; Connor O'Leary; Rahul Ladwa; Kenneth O'Byrne; Brett G.M. Hughes; Chamindie Punyadeera

Heliyon (Jul 2022)

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

Joanna Kapeleris,
Juliana Müller Bark,
Shanon Ranjit,
Darryl Irwin,
Gunter Hartel,
Majid Ebrahimi Warkiani,
Paul Leo,
Connor O'Leary,
Rahul Ladwa,
Kenneth O'Byrne,
Brett G.M. Hughes,
Chamindie Punyadeera

Affiliations

Joanna Kapeleris: Queensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Biomedical Technologies, Saliva and Liquid Biopsy Translational Laboratory Kelvin Grove, QLD, Australia; Translational Research Institute, Woolloongabba, Brisbane, Australia
Juliana Müller Bark: Queensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Biomedical Technologies, Saliva and Liquid Biopsy Translational Laboratory Kelvin Grove, QLD, Australia; Translational Research Institute, Woolloongabba, Brisbane, Australia; Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery, Griffith University, Brisbane, Australia
Shanon Ranjit: Queensland University of Technology, Faculty of Health, School of Biomedical Sciences, Centre for Biomedical Technologies, Saliva and Liquid Biopsy Translational Laboratory Kelvin Grove, QLD, Australia
Darryl Irwin: Agena Biosciences, Bowen Hills, Brisbane, QLD, Australia
Gunter Hartel: QIMR Berghofer Medical Research Institute, Herston Road, Herston, QLD, Australia
Majid Ebrahimi Warkiani: School of Biomedical Engineering, University of Technology Sydney, Sydney, Ultimo NSW, Australia
Paul Leo: Translational Research Institute, Woolloongabba, Brisbane, Australia; Australian Translational Genomics Centre, Queensland University of Technology, Faculty of Health, School of Biomedical Sciences, Woolloongabba, Australia
Connor O'Leary: Translational Research Institute, Woolloongabba, Brisbane, Australia; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Rahul Ladwa: Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; School of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia
Kenneth O'Byrne: Translational Research Institute, Woolloongabba, Brisbane, Australia; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Brett G.M. Hughes: School of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia; The Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia
Chamindie Punyadeera: Translational Research Institute, Woolloongabba, Brisbane, Australia; Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery, Griffith University, Brisbane, Australia; Menzies Health Institute, Griffith University, Gold-Coast, Australia; Corresponding author.

Journal volume & issue: Vol. 8, no. 7
p. e09971

Abstract

Read online

Background: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12–18 months. Liquid biopsy-based biomarkers have emerged as potential candidates for predicting prognosis and response to therapy in NSCLC patients. This pilot study evaluated whether combining circulating tumour cells and clusters (CTCs) and cell-free DNA (cfDNA) can predict progression-free survival (PFS) in NSCLC patients. Methods: CTC and cfDNA/ctDNA from advanced stage NSCLC patients were measured at study entry (T0) and 3-months post-treatment (T1). CTCs were enriched using a spiral microfluidic chip and characterised by immunofluorescence. ctDNA was assessed using an UltraSEEK® Lung Panel. Kaplan-Meier plots were generated to investigate the contribution of the presence of CTC/CTC clusters and cfDNA for PFS. Cox proportional hazards analysis compared time to progression versus CTC/CTC cluster counts and cfDNA levels. Results: Single CTCs were found in 14 out of 25 patients, while CTC clusters were found in 8 out of the 25 patients at T0. At T1, CTCs were found in 7 out of 18 patients, and CTC clusters in 1 out of the 18 patients. At T0, CTC presence and the combination of CTC cluster counts with cfDNA levels were associated with shorter PFS, p = 0.0261, p = 0.0022, respectively. Conclusions: Combining CTC cluster counts and cfDNA levels could improve PFS assessment in NSCLC patients. Our results encourage further investigation on the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.

Published in Heliyon

ISSN: 2405-8440 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Science (General); Social Sciences: Social sciences (General)
Website: https://www.cell.com/heliyon/home

About the journal

Abstract

Keywords